Viewing Study NCT00309205


Ignite Creation Date: 2025-12-25 @ 3:24 AM
Ignite Modification Date: 2025-12-26 @ 2:03 AM
Study NCT ID: NCT00309205
Status: COMPLETED
Last Update Posted: 2009-09-01
First Post: 2006-03-30
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Safety Study of Dapivirine (TMC120) Vaginal Microbicide Gel in Belgium
Sponsor: International Partnership for Microbicides, Inc.
Organization:

Study Overview

Official Title: A Phase I/II Single-Centre Double-Blinded Randomized Study of the Safety and Tolerability of TMC120 Vaginal Microbicide Gel vs. HEC-Based Universal Placebo Gel in Healthy HIV-Negative Women.
Status: COMPLETED
Status Verified Date: 2009-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Approximately 36 HIV-negative women, aged \>18 and \< 50, will be enrolled in this study. Each volunteer will have a 2:1 chance of receiving dapivirine gel versus placebo. The volunteers will receive investigational product for a total of 42 days.
Detailed Description: None

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: